Send by emailPrint this page

At Okairos we are pioneering the development of T-cell based vaccines for major infectious diseases, including hepatitis C, malaria, respiratory syncytial virus and influenza, as well as cancer.

We are a clinical-stage company at the forefront of a new generation of potential medicines, aiming to unlock the as yet untapped significant potential of our proprietary adenovirus vectors in both prophylactic and therapeutic vaccines.

We have the strongest CD8 T-cell responses in the industry to date, a robust pipeline, an experienced management team and a knowledgeable board of directors.

News & Events

GSK strengthens vaccines business with acquisition of Okairos

GlaxoSmithKline today announced that it has acquired Okairos AG, a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash.

TB, HIV and Malaria Vaccine Research Gets Major Boost

Aeras, the University of Oxford and Okairos today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

Okairos initiates Phase I clinical trial evaluating vaccine against RSV infections

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.

Okairos named as one of Windhover’s Top Projects to Watch in infectious diseases

Windhover selects Okairos as one of the most attractive infectious disease opportunities the industry has to offer

T-cell vaccine specialist Okairos named by FierceBiotech as one of the 2012 Fierce 15

FierceBiotech today named Okairos as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.